User Successfully Logged In
User Authenticated!

Library

Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.

97 Results

Poster

A Phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Author(s): Heymach et al.

Tumor type(s): Solid tumors

Compound/Target: HER2 TKI

KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer

Author(s): Lenz et al.

Tumor type(s): Colorectal cancer

Compound/Target: KISIMA-01

ATP128 vaccine with ezabenlimab promotes antigen-specific immune responses in stage IV colorectal cancer in the KISIMA-01 Phase 1b trial

Author(s): Lenz et al.

Tumor type(s): Colorectal cancer

Compound/Target: KISIMA-01

Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPa immune checkpoint inhibitor BI 765063 in patients with advanced solid tumors

Author(s): Champiat et al.

Tumor type(s): Solid tumors

Compound/Target: SIRPa

The beginning of the end for KRAS cancers

Author(s): Kraut et al.

Tumor type(s): Solid tumors

Compound/Target: KRAS 

Meet-the-expert session

A Phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma: Brightline-1

Author(s): Schoffski et al.

Tumor type(s): Liposarcoma

Compound/Target: MDM2-p53

A first-in-human Phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6

Author(s): Falchook et al.

Tumor type(s): Solid tumors

Compound/Target: B7-H6/CD3

A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma

Author(s): Gounder et al.

Tumor type(s): Liposarcoma

Compound/Target: MDM2-p53

A Phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with immune checkpoint inhibitor(s) in patients with advanced solid tumors

Author(s): Yamamoto et al.

Tumor type(s): Liposarcoma

Compound/Target: MDM2-p53

Effect of performance status on treatment outcome with second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line immune checkpoint inhibitor combination therapy

Author(s): Grohe et al.

Tumor type(s): Lung adenocarcinoma

Compound/Target: Triple angio-kinase inhibitor

A Phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours

Author(s): Schoffski et al.

Tumor type(s): Solid tumours

Compound/Target: MDM2-p53

Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy 

Author(s): Grohe et al. 

Tumor type(s): Lung adenocarcinoma 

Compound/Target: Triple angio-kinase inhibitor

A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma

Author(s): Gounder et al.

Tumor type(s): Solid tumors 

Compound/Target: MDM2-p53

A Phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with immune checkpoint inhibitor(s) in patients with advanced solid tumors

Author(s): Tolcher et al.

Tumor type(s): Solid tumor

Compound/Target: MDM2-p53

A phase II/III, randomized, open-label, multicenter study of the MDM2–P53 antagonist BI 907828 vs doxorubicin in the first-line treatment of patients with dedifferentiated liposarcoma: Brightline-1

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations

Author(s): Yamamoto et al.

Tumor type(s): Solid tumors

Compound/Target: HER2 TKI

Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two phase Ia/Ib dose-escalation/expansion trials

Author(s): Yamamoto et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

A Phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

BI 907828: A highly potent MDM2–p53 antagonist suitable for intermittent dose schedules

Author(s): Gollner et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations

Author(s): Heymach et al.

Tumor type(s): Solid tumor

Compound/Target: HER2 TKI

Predictive response biomarkers from Phase I clinical trial of SIRPa inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD-1 inhibitor, in patients with advanced solid tumors

Author(s): Champiat et al.

Tumor type(s): Solid tumors

Compound/Target: SIRPa
 

A Phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma or other selected solid tumours. (Brightline-2)

Author(s): Macarulla et al.

Tumor type(s): Solid tumor

Compound/Target: MDM2-p53

A phase 0/Ia study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM)

Author(s): Sarkaria et al.

Tumor type(s): GBM

Compound/Target: MDM2-p53

A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2

Author(s): Goyal et al.

Tumor type(s): Solid tumor

Compound/Target: MDM2-p53

Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, and MDM2a p53 antagonist

Author(s): Peltzer et al.

Tumor type(s): Solid tumor

Compound/Target: MDM2-p53

Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data

Author(s): Heymach et al.

Tumor type(s): Solid tumor

Compound/Target: HER2 TKI

A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors: safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)

Author(s): LoRusso et al.

Tumor type(s): DDLPS

Compound/Target: MDM2-p53

An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas

Author(s): Gambardella et al.

Tumor type(s): NET

Compound/Target: DLL3/CD3 TcE

Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: focus on neuroendocrine carcinomas

Author(s): Gambardella et al.

Tumor type(s): NET

Compound/Target: DLL3/CD3 TcE

Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs

Author(s): Mazières et al.

Tumor type(s): SCLC 

Compound/Target: DLL3/CD3 TcE

A Phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

Author(s): Schöffski et al.

Tumor type(s): Solid tumors

Compound/Target: MDM2-p53

Beamion LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631) in patients (pts) with advanced solid tumours with HER2 aberrations: latest data

Author(s): Ruiter et al.

Tumor type(s): Solid tumors

Compound/Target: HER2 TKI

Open-label, Phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab

Author(s): Gutierrez et al.

Tumor type(s): Solid tumors

Compound/Target: SIRPα

Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors

Author(s): Calvo et al.

Tumor type(s): Solid tumors

Compound/Target: ezabenlimab

First-in-human, Phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

Author(s): Heymach et al.

Tumor type(s): Solid tumors

Compound/Target: KRAS G12C

Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)

Author(s): Ackermann et al.

Tumor type(s): Solid tumors

Compound/Target: VSV-GP

Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo

Author(s): Schoeps et al.

Tumor type(s): Solid tumors

Compound/Target: VSV-GP

Unmet needs in locally advanced (unresectable)or metastatic dedifferentiated liposarcoma and expectations for clinical trials: an international Delphi consensus study

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Changes in computed tomography features induced by brigimadlin (BI 907828) in patients with liposarcoma: insights from phase 1 studies

Author(s): Schwartz et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Efficacy and safety of brigimadlin (BI 907828), a MDM2–p53 antagonist, in patients with advanced biliary tract cancer: data from two Phase Ia/Ib dose-escalation/expansion trials

Author(s): Macarulla et al.

Tumor type(s): BTC

Compound/Target: MDM2-p53

Ezabenlimab (BI 754091) plus modified docetaxel, cisplatin, and 5-fluorouracil followed by chemoradiotherapy in patients with Stage III squamous cell carcinoma of the anus: early efficacy endpoint results from the Phase II INTERACT-ION study

Author(s): Kim et al.

Tumor type(s): SCAC

Compound/Target: Ezabenlimab

First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with locally advanced solid tumors

Author(s): Champiat et al.

Tumor type(s): Solid tumors

Compound/Target: VSV-GP

A Phase Ib, open-label, dose escalation trial of the delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive glioma

Author(s): van den Bent et al.

Tumor type(s): SCLC

Compound/Target: DLL3/CD3 TcE

Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer

Author(s): Lucas et al.

Tumor type(s): CRC

Compound/Target: anti-SIRPα

Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a Phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin

Author(s): Jaimes et al.

Tumor type(s): DDLPD

Compound/Target: MDM2-p53

Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: a longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study

Author(s): Peltzel et al.

Tumor type(s): DDLPS

Compound/Target: MDM2-p53

Beamion LUNG-2: a phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) muta

Author(s): Johnson et al.

Tumor type(s): NSCLC

Compound/Target: HER2-TKI

Updated data from Beamion LUNG-1, a Phase (Ph) Ia/b trial of the HER2-specific tyrosine kinase inhibitor (TKI), zongertinib (BI 1810631), in patients (pts) with HER2 mutation-positive (m+) NSCLC

Author(s): Opdam et al.

Tumor type(s): NSCLC

Compound/Target: HER2-TKI

A Phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain mutations: Beamion L

Author(s): Wu et al.

Tumor type(s): NSCLC

Compound/Target: HER2-TKI

Presentations

Development and Early Clinical Exploration of an MDM2-P53 Antagonist for Soft Tissue Sarcoma and Other Indications

Author(s): Schoffski et al.

Tumor type(s): Sarcoma

Targeting HER2 and KRAS to Deliver Breakthrough Therapies

Author(s): Smit et al.

Tumor type(s): Solid tumors

T-cell Engagers: Changing the Treatment Paradigm in Solid Tumors

Author(s): Reck et al.

Tumor type(s): Solid tumors

First-in-human dose-escalation trial of the delta-like ligand 3 (DLL3)/CD3 bispecific T-cell engager BI 764532 in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)

Author(s): Wermke et al.

Tumor type(s): SCLC and NEC

Compound/Target: DLL3 TcE

An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas

Author(s): Gambardella et al.

Tumor type(s): NET

Compound/Target: DLL3/CD3 TcE

Improving the Present: Selective HER2 TKI in NSCLC

Author(s): Cho et al.

Tumor type(s): NSCLC

Compound/Target: HER2 TKI

The Past: A Brief History of Personalized Therapy in Lung Cancer

Author(s): Loong et al.

Tumor type(s): Lung Cancer

Compound/Target: 

Advancing Towards the Future: Targeting DLL3 in SCLC

Author(s): Goto et al.

Tumor type(s): SCLC

Compound/Target: DLL3/CD3 TcE

Phase I dose escalation trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients with DLL3+ tumors: focus on SCLC

Author(s): Wermke et al.

Tumor type(s): SCLC

Compound/Target: DLL3/CD3 TcE

Real-world characteristics and outcomes among patients with advanced non-small cell lung cancer and HER2 mutations

Author(s): Heymach et al.

Tumor type(s): NSCLC

Compound/Target: HER2 TKI

Beamion Lung 1, a Phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients with advanced solid tumors with HER2 aberrations

Author(s): Yamamoto et al.

Tumor type(s): Solid tumor

Compound/Target: HER2 TKI

Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Improving HER2 Targeting in NSCLC with Selective TKI

Author(s): Piotrowska et al.

Tumor type(s): NSCLC 

Compound/Target: HER2 TKI

T-cell Engagers: Fighting Solid Tumors from Within

Author(s): Rudin et al.

Tumor type(s): SCLC

Compound/Target: DLL3/CD3 TcE

Longitudinal mutational analysis of TP53 in circulating tumor DNA in the plasma of patients with liposarcoma in a phase I study of brigimadlin (BI 907828), an MDM2-p53 antagonist

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients with solid tumors: safety and efficacy in patients with liposarcoma

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors

Author(s): Heymach et al.

Tumor type(s): Solid tumors

Compound/Target: HER2 TKI

A Phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin (BI 907828): safety and efficacy in patients with dedifferentiated liposarcoma

Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53

Phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS)

Author(s): Reichardt et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53

Beamion LUNG-1, a Phase Ia/b trial of zongertinib (BI 1810631) in patients with solid tumors: focus on patients with HER2 mutation-positive NSCLC

Author(s): Yoh et al.

Tumor type(s): NSCLC

Compound/Target: HER2 TKI

Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors

Author(s): Calvo et al.

Tumor type(s): Solid tumors

Compound/Target: STING

Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumors: focus on Asian patients

Author(s): Kuboki et al.

Tumor type(s): SCLC

Compound/Target: DLL3/CD3 TcE

Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI) in patients (pts) with HER2 aberration-positive solid tumors: updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data

Author(s): Heymach et al.

Tumor type(s): Solid tumors

Compound/Target: HER2-TKI

Infographics

A Phase Ia/Ib, dose-escalation/expansion trial of BI 907828 in combination with immune checkpoint inhibitors(s) in patients with advanced solid tumors (NCT03964233)

Author(s): Yamamoto et al.

Tumor type(s): Solid tumors

Compound/Target: MDM2-p53

A Phase II/III, randomized, open-label, multicenter trial of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma: Brightline-1

Author(s): Schoffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Phase Ia/Ib, dose-escalation/expansion trial of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)

Author(s): Gounder et al.

Tumor type(s): Solid tumors and Sarcoma

Compound/Target: MDM2-p53

Effect of best response to first-line treatment on outcomes with second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line immunochemotherapy

Author(s): Grohe et al.

Tumor type(s): NSCLC

Compound/Target: Triple angio-kinase inhibitor

A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma

Author(s): Gounder et al.

Tumor type(s): Solid tumors and Sarcoma

Compound/Target: MDM2-p53

A Phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with immune checkpoint inhibitor(s) in patients with advanced solid tumors

Author(s): Tolcher et al.

Tumor type(s): Solid tumors

Compound/Target: MDM2-p53

A Phase II/III, randomized, open-label, multicenter study of the MDM2–p53 antagonist BI 907828 vs doxorubicin in the first-line treatment of patients with dedifferentiated liposarcoma: Brightline-1

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

A Phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations

Author(s): Heymach et al.

Tumor type(s): NSCLC

Compound/Target: HER2 TKI

Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data

Author(s): Heymach et al.

Tumor type(s): Solid tumor

Compound/Target: HER2 TKI

First-in-human dose-escalation trial of the delta-like ligand 3/CD3 bispecific T-cell engager BI 764532 in patients with DLL3-positive small-cell lung cancer and neuroendocrine carcinoma

Author(s): Wermke et al.

Tumor type(s): SCLC and NEC

Compound/Target: DLL3

A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors: safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)

Author(s): LoRusso et al.

Tumor type(s): DDLPS

Compound/Target: MDM2-p53

A Phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma or other selected solid tumours. (Brightline-2)

Author(s): Macarulla et al.

Tumor type(s): Solid tumor 

Compound/Target: MDM2-p53

Beamion LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631) in patients (pts) with advanced solid tumours with HER2 aberrations: latest data

Author(s): Ruiter et al.

Tumor type(s): Solid tumors

Compound/Target: HER2 TKI

Phase I dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small cell lung cancer and other neuroendocrine carcinomas (NECs) expressing DLL3

Author(s): Mazières et al.

Tumor type(s): SCLC

Compound/Target: DLL3/CD3 TcE

First-in-human, Phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

Author(s): Heymach et al.

Tumor type(s): Solid tumors

Compound/Target: KRAS G12C

Longitudinal mutational analysis of TP53 in circulating tumor DNA in the plasma of patients with liposarcoma in a phase I study of brigimadlin (BI 907828), an MDM2-p53 antagonist

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients with solid tumors: safety and efficacy in patients with liposarcoma

Author(s): Schöffski et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

Changes in computed tomography features induced by brigimadlin (BI 907828) in patients with liposarcoma: insights from phase 1 studies

Author(s): Schwartz et al.

Tumor type(s): Sarcoma

Compound/Target: MDM2-p53

A Phase Ib, open-label, dose escalation trial of the delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive glioma

Author(s): van den Bent et al.

Tumor type(s): SCLC

Compound/Target: DLL3/CD3 TcE

Beamion LUNG-1, an a Phase Ia/Ib trial of zongertinib (BI 1810631) in patients with solid tumors: focus on patients with HER2 mutation-positive NSCLC

Author(s): Ruiter et al.

Tumor type(s): Solid tumors

Compound/Target: HER2 TKI

A Phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors

Author(s): Doi et al.

Tumor type(s): Solid tumors

Compound/Target: B7-H6/CD3 TcE

DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small ce

Author(s): Peters et al.

Tumor type(s): SCLC

Compound/Target: DLL3/TcE

Beamion LUNG-1, a Phase Ia/b trial zongertinib (BI1810631), in patients with NSCLC harbouring mutations in the HER2 gene: updated data

Author(s): Opdam et al.

Tumor type(s): NSCLC

Compound/Target: HER2-TKI

A Phase III trial of zongertinib (BI 1810631) compared with standard of care in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain mutations: Beamion LUNG-2

Author(s): Wu et al.

Tumor type(s): NSCLC

Compound/Target: HER2-TKI